Thalidomide in dermatology

Wines, Nina; Cooper, Alan; Wines, Michael

doi:10.1046/j.1440-0960.2002.00608.x

Cited by 37 publications

(28 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of thalidomide has been extensively reviewed during more than a decade [1,4,10,11,12,13,14,15,16], focusing on indications for use and focusing on limitations due to thalidomide’s teratogenicity and on its ability to induce neuropathy. However, thalidomide has been used in a comparative study in patients with toxic epidermal necrolysis [17] and it was found that it increased mortality and is therefore contraindicated in this severe dermatological condition.…”

Section: Discussionmentioning

confidence: 99%

Thalidomide in 42 Patients with Prurigo Nodularis Hyde

Andersen

Fogh²

2011

Dermatology

View full text Add to dashboard Cite

The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects. 77 medical records were retrospectively reviewed for the following data: sex, age, age at the beginning of thalidomide treatment, dermatological diagnosis, duration of the skin disease, previous treatments, indications for treatment with thalidomide, effect of treatment, duration of treatment with thalidomide, reasons for cessation of thalidomide treatment, and side effects. 54 patients had PNH. All patients were refractory to standard therapy or had side effects to treatment. 42 patients were treated with thalidomide and the majority of patients experienced clinical improvement. The most common reason for discontinuation of therapy was side effects, the most frequent being peripheral neuropathy and sedation. Thalidomide effectively treats PNH refractory to standard medications. However, physicians must be aware of possible side effects, especially peripheral neuropathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Thalidomide in 42 Patients with Prurigo Nodularis Hyde

Andersen

Fogh²

2011

Dermatology

View full text Add to dashboard Cite

show abstract

“…Nijsten et al have been the first to report this type of side effect [20]. The drug however is considered to be an effective agent in dermatological conditions that are based on immunological and inflammatory disorders [21].…”

Section: Discussionmentioning

confidence: 99%

Thalidomide in patients with malignant pleural mesothelioma

et al. 2005

View full text Add to dashboard Cite

“…The use of thalidomide as a means of manipulating TNF-α protein levels has become increasingly popular in recent years. Although thalidomide is a controversial drug, several research groups are utilizing the backbone of thalidomide to generate analogs for study in several areas to medical research [148–151]. …”

Section: Introductionmentioning

confidence: 99%

Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases

Frankola

Greig²,

Luo³

et al. 2011

CNSNDDT

208

168

View full text Add to dashboard Cite

Inflammatory signals generated within the brain and peripheral nervous system (PNS) direct diverse biological processes. Key amongst the inflammatory molecules is tumor necrosis factor-alpha (TNF-α), a potent pro-inflammatory cytokine that, via binding to its associated receptors, is considered to be a master regulator of cellular cascades that control a number of diverse processes coupled to cell viability, gene expression, synaptic integrity and ion homeostasis. Whereas a self-limiting neuroinflammatory response generally results in the resolution of an intrinsically or extrinsically triggered insult by the elimination of toxic material or injured tissue to restore brain homeostasis and function, in the event of an unregulated reaction, where the immune response persists, inappropriate chronic neuroinflammation can ensue. Uncontrolled neuroinflammatory activity can induce cellular dysfunction and demise, and lead to a self-propagating cascade of harmful pathogenic events. Such chronic neuroinflammation is a typical feature across a range of debilitating common neurodegenerative diseases, epitomized by Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis, in which TNF-α expression appears to be upregulated and may represent a valuable target for intervention. Elaboration of the protective homeostasis signaling cascades from the harmful pathogenic ones that likely drive disease onset and progression could aid in the clinical translation of approaches to lower brain and PNS TNF-α levels and amelioration of inappropriate neuroinflammation.

show abstract

Thalidomide in dermatology

Cited by 37 publications

References 92 publications

Thalidomide in 42 Patients with Prurigo Nodularis Hyde

Thalidomide in 42 Patients with Prurigo Nodularis Hyde

Thalidomide in patients with malignant pleural mesothelioma

Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases

Contact Info

Product

Resources

About